A breakthrough study just published by Dr. Pashtoon Kasi and colleagues (Weill Cornell Medicine) shares the exciting clinical results of a novel checkpoint inhibitor combination therapy, being developed by Agenus Bio, for colorectal cancer treatment.
RareCyte's Orion spatial biology platform played a key role in revealing the mechanisms of action of the treatment, including a unique 'inside-out' (serosa-to-mucosa) tumor regression pattern, and a detailed view of the immune repertoire changes between pre- and post-treatment.
Learn more, read the full review